Impact of initial exposure to calcineurin inhibitors on kidney graft function of patients at high risk to develop delayed graft function

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 1, 2006, Pages 43-52

  Silva, L A ^a   Felipe, C R ^a   Park, S I ^a   Pinheiro Machado, P ^a   Garcia, R ^a   Franco, M ^a   Moreira, S R ^a   Tedesco Silva, Jr ^a   Medina Pestana, J ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclosporine; Delayed graft function; Graft function; Kidney transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VASOACTIVE AGENT;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; RENAL GRAFT DYSFUNCTION; RETROSPECTIVE STUDY; SIDE EFFECT; SLOW GRAFT FUNCTION;

CYTOMEGALOVIRUS;

EID: 30844471180     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/s0100-879x2006000100005     Document Type: Article

References (34)

1. Halloran PF & Hunsicken LG (2001). Delayed graft function: state of the art. American Journal of Transplantation, 1: 115-120.
2. Cosio FG, Qiu W, Henry ML et al. (1996). Factors related to the donor organ are major determinants of renal allograft function and survival. Transplantation, 62: 1571-1576.
3. Ojo AO, Hanson JA, Meier-Kriesche H et al. (2001). Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. Journal of the American Society of Nephrology, 12: 589-597.
4. Meier-Kriesche HU, Port FK, Ojo AO et al. (2000). Effect of waiting time on renal transplant outcome. Kidney International, 58: 1311-1317.
5. Meier-Kriesche HU & Kaplan B (2002). Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation, 74: 1377-1381.
6. Grinyo, JM, Gil-Vernet S, Cruzado JM et al. (2003). Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transplant International, 16: 820-827.
7. Gonwa T, Johnson C, Ahsan N et al. (2003). Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation, 75: 2048-2053.
8. Chang GJ, Mahanty HD, Vincenti F et al. (2000). A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clinical Transplantation, 14: 550-554.
9. Hong JC & Kahan BD (2001). A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation, 71: 1320-1328.
10. Meier-Kriesche HU, Arndorfer JÁ & Kaplan B (2002). Association of antibody induction with short and long-term cause specific mortality in renal transplant recipients. Journal of the American Society of Nephrology, 13: 769-772.
11. Koning OH, Ploeg RJ, van Bockel JH et al. (1997). Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. Transplantation, 63: 1620-1628.
12. Ojo AO, Wolfe RA, Held PJ et al. (1997). Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation, 63: 968-974.
13. Humar A, Johnson EM, Payne WD et al. (1997). Effect of initial slow graft function on renal allograft rejection and survival. Clinical Transplantation, 11: 623-627.
14. Marcen R, Orofino L, Pascual J et al. (1998). Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation, 66: 461-466.
15. McLaren AJ, Jassem W, Gray DW et al. (1999). Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clinical Transplantation, 13: 266-272.
16. Gjertson DW (2000). Impact of delayed graft function and acute rejection on kidney allograft survival. Clinical Transplants, 467-480.
17. Boom H, Mallat MJ, de Fijter JW et al. (2000). Delayed graft function influences renal function, but not survival. Kidney International, 58: 859-866.
18. Gill JS & Pereira BJ (2003). Death in the first year after kidney transplantation: implications for patients on the transplant waiting list. Transplantation, 75: 113-117.
19. Govani MV, Kwon O, Batiuk TD et al. (2002). Creatinine reduction ratio and 24-hour creatinine excretion on post transplant day two: simple and objective tools to define graft function. Journal of the American Society of Nephrology, 13: 1645-1649.
20. Novick AC, Hwei HH, Steinmuller D et al. (1986). Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation, 42: 154-158.
21. Matas AJ, Tellis VA, Quinn TA et al. (1988). Individualization of immediate post-transplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function. Transplantation, 45: 406-409.
22. Arnold AN, Wombolt DG, Whelan TV et al. (2000). Mycophenolate mofetil, with cyclosporine and prednisone, reduces early rejection while allowing the use of less antilymphocytic agent induction and cyclosporine in renal recipients with delayed graft function. Clinical Transplantation, 14: 421-426.
23. Shoskes DA & Cecka JM (1998). Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of a rejection. Transplantation, 66: 1697-1701.
24. Humar A, Ramcharan T, Kandaswamy R et al. (2002). Risk factors for slow graft function after kidney transplants: a multivariate analysis. Clinical Transplantation, 16: 425-429.
25. Park JH, Yang CW, Kim YS et al. (2002). Comparisons of clinocopathological correlations between immediate and slow graft function in renal transplant recipients. Clinical Transplantation, 16 (Suppl 8): 18-23.
26. Troppmann C, Gillingham KJ, Gruessner RW et al. (1996). Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good function at one year after transplantation. Transplantation, 61: 1331-1337.
27. Yokoyama I, Uchida K, Kobayashi T et al. (1994). Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clinical Transplantation, 8: 101-106.
28. Fernandez-Juarez G, Marcen R, Pascual J et al. (2002). Prolonged delayed graft function decreases graft survivals in transplant patients taking cyclosporine. Transplantation Proceedings, 34: 338-339.
29. Giral-Classe M, Hourmant M, Cantarovich D et al. (1998). Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney International, 54: 972-978.
30. Woo YM, Jardine AG, Clark AF et al. (1999). Early graft function and patient survival following cadaveric renal transplantation. Kidney International, 55: 692-699.
31. Abbott KC, Hyppolite IO, Viola R et al. (2002). Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Annals of Epidemiology, 12: 402-409.
32. Maes BD, Kuypers D, Messiaen T et al. (2001). Post-transplantation diabetes mellitus in FK506-treated renal transplant patients: Analysis of incidence and risk factors. Transplantation, 72: 1655-1661.
33. Douzdjian V, Bhaskar S, Baliga PK et al. (1997). Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function. Clinical Transplantation, 11: 294-298.
34. Gonwa TA, Mai ML, Smith LB et al. (2002). Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Clinical Transplantation, 16: 144-149.